Combined Anabolic Therapy

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT06558188
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
45 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Romosozumab — DRUG
    romosozumab 210 milligrams monthly
  • Teriparatide — DRUG
    teriparatide 20 micrograms daily

Study Details

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Key Dates

Start date
Feb 3, 2025
Status verified
Apr 2026
Primary completion
Dec 30, 2027
Completion
Apr 1, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Romosozumab
    romosozumab
  • Active Comparator: Romosozumab and Teriparatide
    romosozumab and teriparatide

Primary Outcome Measure

Lumbar spine areal bone mineral density [ Time Frame: Month 0 to 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Aparna Patnaik, BA
[email protected]
617-726-6129

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MA

Related Studies